282 related articles for article (PubMed ID: 9342580)
1. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
Bindschedler M; Degen P; Flesch G; de Gasparo M; Preiswerk G
Eur J Clin Pharmacol; 1997; 52(5):371-8. PubMed ID: 9272406
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
Müller P; Cohen T; de Gasparo M; Sioufi A; Racine-Poon A; Howald H
Eur J Clin Pharmacol; 1994; 47(3):231-45. PubMed ID: 7867676
[TBL] [Abstract][Full Text] [Related]
5. An interaction study with cimetidine and the new angiotensin II antagonist valsartan.
Schmidt EK; Antonin KH; Flesch G; Racine-Poon A
Eur J Clin Pharmacol; 1998 Feb; 53(6):451-8. PubMed ID: 9551704
[TBL] [Abstract][Full Text] [Related]
6. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
8. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
9. AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Clair MJ; Krombach RS; Hendrick JW; Houck WV; Hebbar L; Kribbs SB; Rios G; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
J Card Fail; 1998 Dec; 4(4):311-23. PubMed ID: 9924853
[TBL] [Abstract][Full Text] [Related]
10. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Azizi M; Bissery A; Lamarre-Cliche M; Ménard J
Hypertension; 2004 Apr; 43(4):785-90. PubMed ID: 15023936
[TBL] [Abstract][Full Text] [Related]
11. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
Morgan JM; Palmisano M; Piraino A; Hirschhorn W; Spencer S; Prasad PP; Ortiz M; Lloyd P
Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
[TBL] [Abstract][Full Text] [Related]
12. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
13. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women.
Fogari R; Preti P; Zoppi A; Corradi L; Pasotti C; Rinaldi A; Mugellini A
Am J Hypertens; 2004 Jan; 17(1):77-81. PubMed ID: 14700518
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
15. Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Azizi M; Blanchard A; Charbit B; Wuerzner G; Peyrard S; Ezan E; Funck-Brentano C; Ménard J
Hypertension; 2013 Jun; 61(6):1239-45. PubMed ID: 23608658
[TBL] [Abstract][Full Text] [Related]
16. Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure.
Boutouyrie P; Beaussier H; Achouba A; Laurent S;
J Hypertens; 2014 Jan; 32(1):108-14. PubMed ID: 24275838
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan.
Daneshtalab N; Lewanczuk RZ; Russell A; Jamali F
J Clin Pharmacol; 2004 Mar; 44(3):245-52. PubMed ID: 14973301
[TBL] [Abstract][Full Text] [Related]
18. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
19. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
LeFebvre J; Shintani A; Gebretsadik T; Petro JR; Murphey LJ; Brown NJ
J Pharmacol Exp Ther; 2007 Mar; 320(3):1261-7. PubMed ID: 17182977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
